Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)

NCT02098837 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
415
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

St Stephens Aids Trust